An interventional study of Atorvastatin and Captopril in Diabetes Mellitus, Type 1, sponsored by Tanta University. Completed at 1 site in Egypt. Open to participants aged 3 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-06-17.
Sponsored by Tanta University · Not applicable, Interventional, and Prevention
Diabetic cardiomyopathy (DCM) is a distinct clinical entity of diabetic heart muscle that describes diabetes associated changes in the structure and function of the myocardium in the absence of coronary artery disease, hypertension, and valvular disease. Oxidative stress plays a critical role in DCM development. DCM can be diagnosed using the novel methods of echocardiography (tissue Doppler imaging, Speckling tracking techniques and more recent real time 4D echocardiography). There is a possible cardioprotective effect of statins, Captopril and L-Carnitine in type 1 diabetic children and adolescents.
3,522 studies on the registry are indexed under Diabetes Mellitus, Type 1; 577 are open to participants now.
This study's enrollment of 150 is above the median of 40 across 2,649 interventional studies indexed under Diabetes Mellitus, Type 1.
Browse Diabetes Mellitus, Type 1 studies →Tanta University is the lead sponsor of 963 studies on the registry; 304 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
25 child with type 1 diabetes mellitus will not receive any cardio protective drug
25 child with type 1 diabetes mellitus will receive Statin (2 mg/kg/day)
Drug: Atorvastatin
25 child with type 1 diabetes mellitus will receive Captopril (0.2 mg/kg/day)
Drug: Captopril
25 child with type 1 diabetes mellitus will receive L-carnitine (50 mg/kg/day)
Drug: L-carnitine
50 healthy children, of matched age and sex, with no symptoms of cardiac diseases
cardio-protective agents
cardio-protective agents
cardio-protective agents
The cardiac changes induced by Simvastatin, captopril and L-Carnitine in type 1 diabetic children and adolescents.
Corrected QT interval(QTc) and QT dispersion in ElectroCardioGram
Time frame: before and after 4 months of receiving cardio-protective agents
The cardiac changes induced by Simvastatin, captopril and L-Carnitine in type 1 diabetic children and adolescents.
Left Ventricular End Systolic Volume (ml). Left Ventricular End Diastolic Volume (ml). Ejection Fraction (EF %) and left ventricular strain using echocardiography.
Time frame: before and after 4 months of receiving cardio-protective agents
The role of Troponin I levels as a cardiac marker for detection of asymptomatic cardiovascular insult in diabetic children.
Serum Cardiac troponin I by Enzyme Linked ImmunoSorbant Assay
Time frame: first day
The role of recent echocardiographic parameters for early detection of silent myocardial dysfunction
Echocardiography
Time frame: first day
Identification of risk factors for developing diabetic cardiac insult.
Time frame: first day
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tanta University